Navigation Links
Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Date:12/10/2012

ssing the same group of ARRY-520-treated patients observed that, for patients retrospectively selected with a lower AAG level, the overall response rate (≥PR) increased to 33% (from 22%) with a median time on study of 6.2 months.  The clinical benefit rate (≥MR) was 50% in the selected population. 

"Multiple myeloma remains an incurable disease, with a significant unmet medical need in patients who are relapsed/refractory to IMiDs and proteasome inhibitors," said Jatin J. Shah, M.D., Assistant Professor, Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center.  "ARRY-520 is a first-in class drug in myeloma with a novel mechanism of action that is very well tolerated and importantly shows very encouraging clinical activity in heavily pre-treated patients who have limited therapeutic options.  Furthermore, I am excited about the potential identification of a selection marker, which would help us identify which patients have the best chance to benefit from receiving ARRY-520."

Interim data from an ongoing combination trial of ARRY-520 with Kyprolis in patients with relapsed or refractory MM who are refractory or intolerant to Velcade® (bortezomib) were also reported at the conference.  The combination has demonstrated early signals of activity, with a 56% clinical benefit rate (≥MR). In addition, it has been well tolerated with limited hematologic toxicity and a manageable side effect profile.

ARRY‑520 is currently advancing in three clinical trials, including the two trials presented at ASH. Continued positive results in any one of these trials will define a clear path to late stage development:

  1. Phase 2 trial in combination with dexamethasone in patients with MM refractory to Revlimid® (lenalidomide), Velcade and dexamethasone therapy. 
  2. Phase 1b trial in combination with Velcade plus dexa
    '/>"/>

SOURCE Array Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
2. John A. Orwin Joins Array BioPharma Board Of Directors
3. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
4. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
5. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
6. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
7. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
8. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
9. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
10. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
11. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... in new orphan drug indications, today announced that the ... as a clinical trial site for the ongoing, multicenter ... glioblastoma multiforme (GBM), the most common and deadly form ...
(Date:4/16/2015)... BETHESDA, Md. , April 16, 2015 /PRNewswire/ ... Bio"), a biotechnology company developing non-toxic DCVax® personalized ... has been included in the Loncar Cancer Immunotherapy ... help investors better track the immunotherapy field within ... founders have selected "the top 25 companies" in ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
(Date:4/15/2015)... England , April 16, 2015 ... developing novel biological drugs to treat cancer and ... and development arm of AstraZeneca, today announced that ... Under the terms of the agreement, Immunocore ... MedImmune,s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
... two British education officals visited Madison to determine ... a time when many Wisconsin leaders are studying ... regions, it is ironic that across the Atlantic, ... and have turned to Wisconsin to export an ...
... -- Aurora Health Care is planning to open a ... new digital hospital will include the latest in digital ... physicians will benefit from enterprise storage and distribution of ... , ,Aurora Health Care established in 1984 is ...
... and political expertise motivates Wisconsins State Senator to trim ... and services. We want to stimulate venture ... to qualified venture funds as well as expand the ... create a bi-partisan effort to pass an end-to-end economic ...
Cached Biology Technology:Aurora Selects New Imaging Technology 2WTN Interview: Senator Ted Kanavas 2WTN Interview: Senator Ted Kanavas 3WTN Interview: Senator Ted Kanavas 4WTN Interview: Senator Ted Kanavas 5WTN Interview: Senator Ted Kanavas 6WTN Interview: Senator Ted Kanavas 7WTN Interview: Senator Ted Kanavas 8
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... New Mexico, March 3, 2010Two teams of researchersincluding Los ... Sydeaka Watson, and James Szingerhave announced an HIV vaccination ... and depth of immune responses in rhesus monkeys. Rhesus ... testing HIV vaccines. The research appeared in two ...
... release is available in Spanish . ... nutrition savvyplus physical fitness skillsare emerging from scientific studies ... example, investigators Craig A. Johnston, John P. Foreyt and ... of their earlier studies in which many of their ...
... Far from being a food spoiler, the fluorescent lighting ... fresh spinach, scientists are reporting. The finding could lead ... value of spinach and perhaps other veggies, they suggest ... Agricultural and Food Chemistry . Gene Lester, Donald ...
Cached Biology News:HIV vaccine strategy expands immune responses 2Kids lose pounds, gain fitness in Houston study 2
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... designer enzyme that enables RT-PCR in ... enzyme allows reverse transcription and PCR ... temperatures (65C), which helps to remove ... results in highly stringent, accurate annealing ...
... Mch3 Lyophilized solid. ... regulation and kinetics, cleavage of target substrates, and inhibitor ... One unit is defined as the amount ... Cat. No. 235400 per hour at 37 C at ...
Biology Products: